Skip to main content
PMC home page
Journal of Cachexia, Sarcopenia and Muscle logoLink to Journal of Cachexia, Sarcopenia and Muscle
editorial
. 2016 Sep 6;7(4):391–395. doi: 10.1002/jcsm.12142

Moving upwards – the journal of cachexia, sarcopenia and muscle in 2016

Stephan von Haehling 1,✉, Nicole Ebner 1, Stefan D Anker 1
PMCID: PMC5011813  PMID: 27625918

The good news first, the Journal of Cachexia, Sarcopenia and Muscle (JCSM) has not only maintained its impact factor, but it has even increased it again, now reaching 7.883 as has been published by Thomson Scientific a few weeks ago. This places JCSM again as the number 9 ranked journal amongst all journals in ‘Medicine, General and Internal’ (Table 1) and as number 2 ranking publication amongst all nutrition journals, amongst which; however, JCSM is still not offficially listed by Thomson Scientific (Table 2). This new impact factor re‐confirms the inaugural impact factors of 7.413 for 2013 and 7.315 for 2014. As before, we would like to sincerely thank all authors, reviewers and editorial board members for their great efforts to produce JCSM at good quality, and we greatly appreciate and value also the interest and support of all those who enjoy reading JCSM and cite the papers published there.

Table 1.

Top ten journals in the field ‘Medicine: General & Internal’, adapted from reference 1

Journal name Impact factor 2016 Items published in 2014 & 2015
1 New England journal of medicine 59.558 701
2 Lancet 44.002 547
3 Journal of the American medical association (JAMA) 37.684 449
4 British medical journal 19.697 519
5 Annals of internal medicine 16.440 325
6 JAMA internal medicine 14.000 332
7 PLOS medicine 13.585 246
8 BMC medicine 8.005 379
9 Jounal of cachexia sarcopenia and muscle 7.883 60
10 Journal of internal medicine 7.803 198
Open in a new tab

Table 2.

Top ten journals in the field ‘Nutrition & Dietetics’, where the journal of cachexia, sarcopenia and muscle is officially not listed

Journal name Impact factor 2016 Items published
in 2014 & 2015
1 Progress in lipid research 11.238 63
2 Annuals review of nutrition 6.784 37
3 American journal of clinical nutrition 6.703 671
4 Nutrition reviews 5.591 149
5 Critical reviews in food science and nutrition 5.492 185
6 International journal of obesity 5.337 484
7 Proceedings of the nutrition society 4.703 111
8 Journal of nutritional biochemistry 4.668 398
9 Advances in nutrition 4.576 158
10 Clinical nutrition 4.487 318
Open in a new tab

This year is special for JCSM for several reasons. One is the publication of an additional (5th) issue in May this year, the other the launch dedicated daughter journals. Indeed, JCSM appears to have sparked more scientific interest in the field of body wasting, cachexia and sarcopenia; and thus, the number of submissions to the main journal remains on the increase. With a 78% rejection rate – knowing that we have to decline publication of many good papers, simply for lack of space – we hope to be able to give some of these a home in our new daughter journals – JCSM Rapid Communications and JCSM Clinical Reports. These journals will be published online only on an open access basis, and we hope that they will help to create a family of journals dedicated to this fascinating field of research into cachexia, sarcopenia and muscle, and that they will help in clinical decision making and in serving as a source of clinical information and case reports as well.

The main journal, JCSM, at the time of this writing this editorial on 18 July 2016, the journal has received 158 submissions in 2016 alone (Figure 1). Last year at this time, we had received 106 submissions .51 Given these higher numbers of submissions, in 2017, we will move to six issues per year to allow publication of more accepted papers. If all goes well, in 2018, we could then possibly move to publication of eight issues per year.

Figure 1.

Figure 1

Open in a new tab

Number of manuscript submissions to the Journal of Cachexia, Sarcopenia and Muscle by year of publication. *Numbers for 2016 are estimated on the number of submissions until 18 July 2016 (Reprinted from 51).

We are working hard to provide a timely peer review, which is not always easy, as it is difficult at times to find appropriate reviewers. Articles that are available for the longest time are – not surprisingly – those that have been cited most (Table 3). Our ‘facts and numbers’ editorials remain popular (Tables 4 and 5), and we invite our readers to submit their work or to suggest topics for ‘facts and numbers’ editorials that are relevant to our readers.

Table 3.

Top twenty of best cited articles since first publication of the journal of cachexia, sarcopenia and muscle

First author Title Type Year Times cited Reference
1. von Haehling Cachexia as a major underestimated and unmet medical need: facts and numbers Editorial 2010 181 2
2. von Haehling An overview of sarcopenia: facts and numbers on prevalence and clinical impact Editorial 2010 94 3
3. Dalton The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial Original Article 2011 88 4
4. Lenk Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training Review 2010 86 5
5. Mak Wasting in chronic kidney disease Review 2011 66 6
6. Fanzani Molecular and cellular mechanisms of skeletal muscle atrophy: an update Review 2012 63 7
7. Elkina The role of myostatin in muscle wasting: an overview. Review 2011 63 8
8. Cesari Biomarkers of sarcopenia in clinical trials‐recommendations from the International Working Group on Sarcopenia Original Article 2012 60 9
9. Lainscak Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease Original Article 2011 55 10
10. Morley From sarcopenia to frailty: a road less traveled Editorial 2014 54 11
11. von Haehling From muscle wasting to sarcopenia and myopenia: update 2012 Editorial 2012 52 12
12. Lainscak The obesity paradox in chronic disease: facts and numbers Editorial 2012 44 13
13. Patel Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross‐sectional study and review of literature Review 2013 43 14
14. Fearon Myopenia‐a new universal term for muscle wasting Editorial 2011 43 15
15. Sakuma Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass Review 2012 42 16
16. Schefold Intensive care unit‐acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock Review 2010 41 17
17. Busquets Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance Original Article 2012 39 18
18. Wakabayashi Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management Review 2014 37 19
19. Farkas Cachexia as a major public health problem: frequent, costly, and deadly Review 2013 37 20
20. Rozentryt The effects of a high‐caloric protein‐rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double‐blind pilot study Original Article 2010 35 21
Open in a new tab

Table 4.

Top twenty of best cited articles published 2014 in the journal of cachexia, sarcopenia and muscle

First author Title Type Year Times cited Reference
1. Morley From sarcopenia to frailty: a road less traveled Editorial 2014 54 11
2. Wakabayashi Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management Review 2014 37 19
3. von Haehling Prevalence, incidence and clinical impact of cachexia: facts and numbers‐update 2014 Editorial 2014 29 22
4. Morley Are we closer to having drugs to treat muscle wasting disease? Editorial 2014 26 23
5. Anker Muscle wasting disease: a proposal for a new disease classification Editorial 2014 24 24
6. Ebner Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies Meeting Report 2014 23 25
7. Heymsfield Assessing skeletal muscle mass: historical overview and state of the art Review 2014 21 26
8. Pietra Anamorelin HCI (ONO‐7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia‐cachexia syndrome: preclinical profile Original Article 2014 20 27
9. Morley Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology‐update 2014 Editorial 2014 17 28
10. Fragala Biomarkers of muscle quality: N‐terminal propeptide of type III procollagen and C‐terminal agrin fragment responses to resistance exercise training in older adults Original Article 2014 15 29
11. Toledo Formoterol in the treatment of experimental cancer cachexia: effects on heart function Original Article 2014 13 30
12. Rhee Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? Editorial 2014 12 31
13. Argiles Cachexia: a problem of energetic inefficiency Review 2014 11 32
14. Poetsch The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats Original Article 2014 11 33
15. Henwood Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility Original Article 2014 10 34
16. Ormsbee Osteosarcopenic obesity: the role of bone, muscle, and fat on health Review 2014 10 35
17. Alchin Sarcopenia: describing rather than defining a condition Review 2014 9 36
18. Mirza Attenuation of muscle wasting in murine C2C12 myotubes by epigallocatechin‐3‐gallate Original Article 2014 9 37
19. Kirkman Anabolic exercise in haemodialysis patients: a randomised controlled pilot study Original Article 2014 8 38
20. Palus Muscle wasting: an overview of recent developments in basic research Review 2014 8 39
Open in a new tab

Table 5.

Top ten of the best cited articles published 2015 in the journal of cachexia, sarcopenia and muscle

First author Title Type Year Times cited Reference
1. Chen Ghrelin prevents tumour‐ and cisplatin‐induced muscle wasting: characterization of multiple mechanisms involved Original Article 2015 7 40
2. Sasso A framework for prescription in exercise‐oncology research Editorial 2015 6 41
3. Stephens Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients Original Article 2015 6 42
4. Calvani Biomarkers for physical frailty and sarcopenia: state of the science and future developments Review 2015 4 43
5. Ezeoke Pathophysiology of anorexia in the cancer cachexia syndrom Review 2015 4 44
6. Fearon Request for regulatory guidance for cancer cachexia intervention trials Editorial 2015 4 45
7 Morley Rapid screening for sarcopenia Editorial 2015 3 46
8. Browen Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training Review 2015 4 47
9. Faber Improved body weight and performance status and reduced serum PGE(2) levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro‐esophageal junction Original Article 2015 4 48
10. Trobec Influence of cancer cachexia on drug liver metabolism and renal elimination in rats Original Article 2015 4 49
Open in a new tab

Finally, we would like to draw your attention to the up‐coming Cachexia Conference, to be held on December 10–11, 2016 in Berlin, Germany. The conference now goes annually, and it has been a source of stimulating ideas and exchange between clinicians and researchers in the field of cachexia and wasting. More information can be found at the following link: http://society‐scwd.org.

Conflict of interest

None declared.

Acknowledgements

The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia and Muscle.52

von Haehling, S. , Ebner, N. , and Anker, S. D. (2016) Moving upwards – the journal of cachexia, sarcopenia and muscle in 2016. Journal of Cachexia, Sarcopenia and Muscle, 7: 391–395. doi: 10.1002/jcsm.12142.

References

  • 1.n.d www.webofknowledge.com (accessed 18/07/2016).
  • 2. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010;1:1–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010;1:129–133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS. The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153–161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2010;1:9–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar‐Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle 2011;2:9–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Fanzani A, Conraads VM, Penna F, Martinet W. Molecular and cellular mechanisms of skeletal muscle atrophy: an updatee. J Cachexia Sarcopenia Muscle 2012;3:163–79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle 2011;2:143–151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, Anker SD, Rutkove S, Vrijbloed JW, Isaac M, Rolland Y, M'rini C, Aubertin‐Leheudre M, Cedarbaum JM, Zamboni M, Sieber CC, Laurent D, Evans WJ, Roubenoff R, Morley JE. Vellas B for the international working group on sarcopenia. Biomarkers of sarcopenia in clinical trials‐recommendations from the international working group on sarcopenia. J Cachexia Sarcopenia Muscle 2012;3:181–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Lainscak M, von Haehling S, Doehner W, Sarc I, Jeric T, Ziherl K, Kosnik M, Anker SD, Suskovic S. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle 2011;2:81–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Morley JE, von Haehling S, Anker SD, Vellas B. From sarcopenia to frailty: a road less traveled. J Cachexia Sarcopenia Muscle 2014;5:5–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle 2012;3:213–217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Lainscak M, von Haehling S, Doehner W, Anker SD. The obesity paradox in chronic disease: facts and numbers. J Cachexia Sarcopenia Muscle 2012;3:1–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Patel SS, Molnar MZ, Tayek JA, Ix JH, Noori N, Benner D, Heymsfield S, Kopple JD, Kovesdy CP, Kalantar‐Zadeh K. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross‐sectional study and review of literature. J Cachexia Sarcopenia Muscle 2013;4:19–29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Fearon K, Evans WJ, Anker SD. Myopenia‐a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle 2011;2:1–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Sakuma K, Yamaguchi A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle 2012;2:77–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Schefold JC, Bierbrauer J, Weber‐Carstens S. Intensive care unit‐acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock. J Cachexia Sarcopenia Muscle 2010;1:147–157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Busquets S, Toledo M, Orpí M, Massa D, Porta M, Capdevila E, Padilla N, Frailis V, López‐Soriano FJ, Han HQ, Argilés JM. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle 2012;3:37–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Wakabayashi H, Sakuma K. Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management. J Cachexia Sarcopenia Muscle 2014;5:269–277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Farkas J, von Haehling S, Kalantar‐Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle 2013;4:173–178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar‐Zadeh K, Polonski L, Anker SD. The effects of a high‐caloric protein‐rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double‐blind pilot study. J Cachexia Sarcopenia Muscle 2010;1:35–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers‐update 2014. J Cachexia Sarcopenia Muscle 2014;5:261–263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Morley JE, von Haehling S, Anker SD. Are we closer to having drugs to treat muscle wasting disease? J Cachexia Sarcopenia Muscle 2014;5:83–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, von Haehling S, Kalantar‐Zadeh K. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014;5:1–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S. Highlights from the 7th cachexia congerence: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle 2014;5:27–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Heymsfield SB, Adamek M, Gonzalez MC, Jia G, Thomas DM. Assessing skeletal muscle mass: historical overview and state of the art. J Cachexia Sarcopenia Muscle 2014;5:9–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Pietra C, Takeda Y, Tazawa‐Ogata N, Minami M, Xia YF, Duus EM, Northrup R. Anamorelin HCI (ONO‐7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia‐cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle 2014;5:329–337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology‐update 2014. J Cachexia Sarcopenia Muscle 2014;5:253–259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Fragala MS, Jajtner AR, Beyer KS, Townsend JR, Emerson NS, Scanlon TC, Oliveira LP, Hoffman JR, Stout JR. Biomarkers of muscle quality: N‐terminal propeptide of type III procollagen and C‐terminal agrin fragment responses to resistance exercise training in older adults. J Cachexia Sarcopenia Muscle 2014;5:139–148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Toledo M, Springer J, Busquets S, Tschirner A, López‐Soriano FJ, Anker SD, Argilés JM. Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J Cachexia Sarcopenia Muscle 2014;5:315–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Rhee CM, Kalantar‐Zadeh K. Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? J Cachexia Sarcopenia Muscle 2014;5:315–320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Argilés JM, Fontes‐Oliveira CC, Toledo M, López‐Soriano FJ, Busquets S. 34Cachexia: a problem of energetic inefficiency. J Cachexia Sarcopenia Muscle 2014;5:279–286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Pötsch MS, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J, Coats AJ, Anker SD, Springer J. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle 2014;5:149–158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Henwood TR, Keogh JW, Reid N, Jordan W, Senior HE. Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility. J Cachexia Sarcopenia Muscle 2014;5:229–236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Ormsbee MJ, Prado CM, Ilich JZ, Purcell S, Siervo M, Folsom A, Panton L. Osteosarcopenic obesity: the role of bone, muscle, and fat on health. J Cachexia Sarcopenia Muscle 2014;5:183–192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Alchin DR. Sarcopenia: describing rather than defining a condition. J Cachexia Sarcopenia Muscle 2014;5:265–268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Mirza KA, Pereira SL, Edens NK, Tisdale MJ. Attenuation of muscle wasting in murine C2C12 myotubes by epigallocatechin‐3‐gallate. J Cachexia Sarcopenia Muscle 2014;5:339–345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Kirkman DL, Mullins P, Junglee NA, Kumwenda M, Jibani MM, Macdonald JH. Anabolic exercise in haemodialysis patients: a randomised controlled pilot study. J Cachexia Sarcopenia Muscle 2014;5:199–207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Palus S, von Haehling S, Springer J. Muscle wasting: an overview of recent developments in basic research. J Cachexia Sarcopenia Muscle 2014;5:193–198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Chen JA, Splenser A, Guillory B, Luo JH, Mendiratta M, Belinova B, Halder T, Zhang GH, Li YP, Garcia JM. Ghrelin prevents tumour‐ and cisplatin‐induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle 2015;6:132–143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise‐oncology research. J Cachexia Sarcopenia Muscle 2015;6:115–124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Stephens NA, Skipworth RJE, Gallagher IJ, Greig CA, Guttridge DC, Ross JA, Fearon KCH. Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle 2015;6:53–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Calvani R, Marini F, Cesari M, Tosato M, Anker SD, von Haehling S, Miller RR, Bernabei R, Landi F, Marzetti E. Group Author(s): SPRINTT Consortium. Biomarkers for physical frailty and sarcopenia: state of the science and future developments. J Cachexia Sarcopenia Muscle 2015;6:278–286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle 2015;6:287–302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Fearon KCH, Argiles JM, Baracos VE, Bernabei R, Coats AJS, Crawford J, Deutz NE, Doehner W, Evans WJ, Ferrucci L, Garcia JM, Gralla RJ, Jatoi A, Kalantar‐Zadeh K, Lainscak M, Morley JE, Muscaritoli M, Polkey MI, Rosano G, Rossi‐Fanelli F, Schols AM, Strasser F, Vellas B, von Haehling S, Anker SD. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle 2015;6:272–274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Morley JE, Cao L. Rapid screening for sarcopenia. J Cachexia Sarcopenia Muscle 2015;6:312–314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2015;6:197–207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Faber J, Uitdehaag MJ, Spaander M, van Steenbergen‐Langeveld S, Vos P, Berkhout M, Lamers C, Rumke H, Tilanus H, Siersema P, van Helvoort A, van der Gaast A. Improved body weight and performance status and reduced serum PGE(2) levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro‐esophageal junction. J Cachexia Sarcopenia Muscle 2015;6:32–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Trobec KC, Kos MK, Trontelj J, Grabnar I, Tschirner A, Palus S, Anker SD, Springer J, Lainscak M. Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. J Cachexia Sarcopenia Muscle 2015;6:45–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. von Haehling S, Anker SD. More colour to the Journal: new style, new publisher, but still cachexia. Sarcopenia and Muscle J Cachexia Sarcopenia Muscle 2015;6:1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. von Haehling S, Anker SD. Moving on up: the journal of cachexia, sarcopenia and muscle. J Cachexia Sarcopenia Muscle 2015;6:193–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015. J Cachexia Sarcopenia Muscle 2015;6:315–6. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Cachexia, Sarcopenia and Muscle are provided here courtesy of Wiley

RESOURCES